Robertsfoged6464

benthamscience.net.BACKGROUND Hospital acquired (HA) infections are caused due to E. coliwhich is resistant to multiple drugs particularly to fluroquinolone class of drugs. Urinary tract infections (UTI) affects people in the community and in hospitals. 150 million people per annum are suffering from UTI worldwide. METHODS In this present study we designed 36 novel coumarin derivatives, also we predicted pharmacokinetic and toxicity parameters. Docking studies were also carriedand all the compounds were evaluated for antibacterial activity againstresistant quinolone E. coli strain ATCC 25922. It was interesting to note thatthe introduction of electron withdrawing group on the aromatic ringresulted in compounds with increased antibacterial activity which is observed in compound 6 (with4-nitro substitution), compound 23(chloro) and compound 30(chloro, nitro). RESULTS From the MIC results, was observed that compounds 6, 23 and 30 showed higher activity with 0.5µg/ml, 0. 12 µg/ml, 0.5 µg/mlrespectively. Docking studies were performed with the activesite of DNA gyrase (PDB ID 4CKK ).The maximum binding energy was found to be -10.7Kcal/mol. CONCLUSION From the study it was found that 3 compounds were potentially active against quinolone resistant E. coli strains. This study can be further extended for in vivo evaluation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Nickel(II) metal-organic framework (Ni-MOF) was used as an efficient catalyst for the synthesis of 2-aryl benzimidazole and benzothiazole derivatives. Ni-MOF was prepared using nickel(II) nitrate hexahydrate and 4,4'- diaminodiphenyl sulfone (DDS), then characterized via XRD, FE-SEM, EDX, FT-IR, BET, and TGA/DTG. The catalyst was then used in the synthesis of some benzimidazole and benzothiazole derivatives. It was found to be an efficient method for the preparation of 2-aryl benzimidazole and benzothiazole derivatives in good to excellent yields at room temperature. The catalyst was easily recovered and reused five times without substantial loss in activity. This procedure has further advantages including mild and environmentally benign conditions, easy workup, simple procedure, high yields, recyclability and nontoxicity of the catalyst. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.In the present work, SO3H-functionalized zeolite-Y (NSZ) was prepared from the reaction of zeolite-NaY with chlorosulfonic acid. The NSZ was used as an excellent solid acid catalyst for one-pot, three-component synthesis of 2-aryl-N-benzimidazole-4-thiazolidinones via condensation of 2-aminobenzimidazole, aromatic aldehydes and thioglycolic acid, in H2O-acetone at room temperature. Then, zeolo sulfuric acid was applied for the synthesis of tri-substituted imidazole derivatives via the one-pot and solvent-free cyclo-condensation of different aldehydes, benzil and ammonium acetate. This efficient catalytic approach offers several advantages, such as excellent yields and high purity, inexpensive procedure and ease of product isolation, the use of nontoxic and heterogeneous acid catalyst, shorter reaction times and milder conditions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.BACKGROUND Evidence regarding the association between HIV viral load (VL) and hypertension is inconsistent. In this study, we investigated the relationship using viremia copy-years (VCY), a cumulative measure of HIV plasma viral burden. METHODS Data were analyzed for 686 PLWH in the Florida Cohort Study who had at least five years of VL data before the baseline. VL data were extracted from Enhanced HIV/AIDS Reporting System (eHARS) and used to define peak VL (pVL), recent VL (rVL), and undetectable VL (uVL rVL5.7) for analysis. Hypertension was determined based on hypertension diagnosis from medical records. Selleck SBE-β-CD Multivariable logistic regression was used for association analysis. RESULTS Of the total sample, 277 (40.4%) participants were hypertensive. Compared to the participants with lowest VCY ( less then 2.7 log10 copy × years/mL), the odds ratios (OR) and 95% confidence interval [95% CI] for hypertension of the remaining four groups, in order, were 1.91 [1.11, 3.29], 1.91 [1.03, 3.53], 2.27 [1.29, 3.99], and 1.25 [0.65, 2.42], respectively, controlling for confounders. The association was independent of pVL, rVL, and uVL, each of which was not statistically significant associations with hypertension. CONCLUSION Persistent HIV infection is a risk factor for hypertension among PLWH. Information provided by VCY is more effective than single time-point VL measures in investigating HIV infection-hypertension relationship. Findings of this study support the significance of continuous viral suppression in hypertension prevention among PLWH. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Amyloid-β (Aβ) has long been shown to be critical in Alzheimer's disease pathophysiology. Microglia contributes to the earliest responses to Aβ buildup, by direct interaction through multiple receptors. Microglial cells operate Aβ clearance and trigger inflammatory/regenerative processes that take place in the long years of silent disease progression that precede symptomatic appearance. But in time and with aging, the fine balance between pro- and anti-inflammatory activity of microglia deranges, negatively impacting its Aβ-clearing ability. Furthermore, in recent years, microglial activation has proven to be much more complex than the mere dichotomic pro/anti-inflammatory polarization previously accepted. Microglia can display a wide spectrum of phenotypes, which can even be mixed. On these basis, it appears evident that while pharmacological intervention aiding microglia to prolong its ability to cope with Aβ buildup could be extremely relevant, its feasibility is hampered by such high complexity which still needs to be completely understood. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.